The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification

Dachuan Zeng(Children's Hospital of Chongqing Medical University), Zhenglan Huang(Chongqing Medical University)
Experimental Hematology and Oncology
May 27, 2022
Cited by 14


Related Papers